Hostname: page-component-74656f9884-2dmjx Total loading time: 0 Render date: 2026-11-07T14:56:43.291Z Has data issue: false hasContentIssue false

Iron status and risk of iron disorders in neonates: A narrative review of recent studies in animal models

Published online by Cambridge University Press:  24 February 2025

Xiuying Wang
Affiliation:
Laboratory of Iron Molecular Biology, Department of Molecular Biology, Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Jastrzębiec, Poland
Paweł Lipiński
Affiliation:
Laboratory of Iron Molecular Biology, Department of Molecular Biology, Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Jastrzębiec, Poland
Magdalena Ogłuszka
Affiliation:
Department of Genomics and Biodiversity, Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Jastrzębiec, Poland
Rafał Radosław Starzyński*
Affiliation:
Laboratory of Iron Molecular Biology, Department of Molecular Biology, Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Jastrzębiec, Poland
*
Corresponding author: Rafał Radosław Starzyński; Email: r.starzynski@igbzpan.pl
Rights & Permissions [Opens in a new window]

Abstract

The iron regulation mechanisms are not exactly the same between adulthood and the early postnatal period. Also, neonatal iron status is different in full-term versus preterm infants because the prenatal/gestational period, when hepatic iron accumulates, is shortened. Newborns, especially premature infants, are at high risk of iron deficiency due to inadequate iron stores, which constitute the primary source of iron to satisfy the neonate’s increasing iron requirements. In addition, frequent blood transfusions and congenital haemochromatosis may induce iron overload in the affected neonate. To understand the cause of neonatal iron deficiency/overload and to promote the development of effective therapeutic interventions in humans, different animal models have been generated by genetic engineering, low-/high-iron diets, phlebotomy/transfusion and surgical manipulation. These models use various laboratory and domestic animals to study iron imbalance. They serve as surrogate models for experiments that are ethically or practically unfeasible to conduct on human neonates. Although an animal model for studying neonatal iron disorders may not fully replicate the complexities of human diseases, it is designed to model specific aspects of these conditions. Combined data from multiple models can help to offset the limitations inherent in each individual model. In this review, we outline approaches to induce neonatal iron disorders, current animal models of full-term and preterm neonates, and recommendations for diagnosis.

Information

Type
Review Article
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of The Nutrition Society
Figure 0

Fig. 1. Systemic iron turnover in the neonate. Duodenal enterocytes absorb two forms of dietary iron, non-haem and haem iron, through different absorption mechanisms. Haem uptake by enterocytes is primarily mediated by haem carrier protein 1 (HCP1) and possibly by haem responsive gene 1 (HRG1)(18–20). Inside enterocytes, haem is catabolised by the enzyme haem oxygenase 1 (HO1) to elemental iron, biliverdin and carbon monoxide(20,21). In turn, by means of iron reductase duodenal cytochrome b (DcytB) and divalent metal transporter 1 (DMT1), non-haem iron crosses the apical membrane of the intestinal epithelial cell to enter the cytoplasm(22). After that, iron enters the labile iron pool (LIP) in the cytosol, a source of iron for haem synthesis and iron–sulphur cluster biogenesis. The cytoplasmic iron is subsequently incorporated into iron-containing proteins, stored in the iron storage protein ferritin, or exported into the circulation by the only known iron exporter ferroportin, with the participation of the copper-dependent ferroxidase hephaestin (or glycosylphosphatidylinositol-linked, membrane-bound ceruloplasmin, GPI-Cp in other cell types)(23–26). In the bloodstream, iron is bound by transferrin and taken up by hepatocytes, erythroblasts and other cells through transferrin receptor 1 (TFR1)-mediated endocytosis(23). The potential pathway of haem iron export from enterocytes involves the transfer of intact haem (not catabolised by HO1) across the basolateral membrane by feline leukaemia virus subgroup C cellular receptor 1 (FLVCR1) to the blood, where it is captured by haemopexin and delivered in the form of haem–haemopexin (Haem–Hx) via receptor CD91 to various sites in the body(20,27,28). Other pathways that may contribute to early iron absorption include lactoferrin receptor-mediated process, pinocytosis and gut microbiota(29,30). Iron recirculation by tissue macrophages, which phagocytose senescent erythrocytes and rapidly degrade the haem released from haemoglobin through the catabolic activity of HO-1, ensures a major part of daily iron supply to erythroid precursors(31). Systemic iron homeostasis is regulated by hepcidin, a hormone secreted by the hepatocytes(32). In cases of iron deficiency, low hepcidin facilitates the unimpeded ferroportin function of professional iron exporter cells(32). When the organism is saturated with iron, the hepcidin blood level increases, and this peptide has a greater potential to interact with ferroportin and, consequently, to reduce iron transfer into the bloodstream(32). In this process, bone morphogenetic protein 6 (BMP6) acts as an ‘iron sensor’(33,34). Its transcription in liver sinusoidal endothelial cells (LSECs) is induced by high iron levels(33,34). BMP6 is then released from LSECs and has a stimulatory paracrine effect on hepcidin expression in hepatocytes by binding to BMP receptor (BMPR)(33,34). Solid lines represent confirmed pathways, while dashed lines indicate proposed pathways that have yet to be confirmed.

Figure 1

Table 1. Examples of neonatal animal models of iron deficiency and overload